Ravangard R, Ghanbari M, Attar A, Jafari A
Health Sci Rep. 2024; 7(7):e2240.
PMID: 38974330
PMC: 11225077.
DOI: 10.1002/hsr2.2240.
Shah K, Willson M, Agresta B, Morton R
Pharmacoecon Open. 2022; 7(1):49-62.
PMID: 36121638
PMC: 9929017.
DOI: 10.1007/s41669-022-00364-0.
Jowett S, Kodabuckus S, Ford G, Hobbs F, Lown M, Mant J
Hypertension. 2022; 79(5):1122-1131.
PMID: 35266409
PMC: 8997697.
DOI: 10.1161/HYPERTENSIONAHA.121.18726.
Berkelmans G, Greving J, van der Graaf Y, Visseren F, Dorresteijn J
Diagn Progn Res. 2020; 4:4.
PMID: 32318625
PMC: 7161238.
DOI: 10.1186/s41512-020-00072-5.
de Jong L, Groeneveld J, Stevanovic J, Rila H, Tieleman R, Huisman M
PLoS One. 2019; 14(9):e0222658.
PMID: 31527894
PMC: 6748426.
DOI: 10.1371/journal.pone.0222658.
Cost-Effectiveness of Telemonitoring and Self-Monitoring of Blood Pressure for Antihypertensive Titration in Primary Care (TASMINH4).
Monahan M, Jowett S, Nickless A, Franssen M, Grant S, Greenfield S
Hypertension. 2019; 73(6):1231-1239.
PMID: 31067190
PMC: 6510405.
DOI: 10.1161/HYPERTENSIONAHA.118.12415.
Cost-effectiveness evaluation of the 45-49 year old health check versus usual care in Australian general practice: A modelling study.
Si S, Moss J, Karnon J, Stocks N
PLoS One. 2018; 13(11):e0207110.
PMID: 30412596
PMC: 6226178.
DOI: 10.1371/journal.pone.0207110.
Multitarget Effects of Danqi Pill on Global Gene Expression Changes in Myocardial Ischemia.
Wang Q, Meng H, Zhang Q, Shi T, Zhang X, Shao M
Int J Genomics. 2018; 2018:9469670.
PMID: 29487863
PMC: 5816862.
DOI: 10.1155/2018/9469670.
Use of relative survival to evaluate non-ST-elevation myocardial infarction quality of care and clinical outcomes.
Hall M, Alabas O, Dondo T, Jernberg T, Gale C
Eur Heart J Qual Care Clin Outcomes. 2018; 1(2):85-91.
PMID: 29474594
PMC: 5805109.
DOI: 10.1093/ehjqcco/qcv011.
Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis.
Hanhart J, Comaneshter D, Freier-Dror Y, Vinker S
Graefes Arch Clin Exp Ophthalmol. 2018; 256(4):651-663.
PMID: 29429131
DOI: 10.1007/s00417-018-3917-9.
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
Arrieta A, Hong J, Khera R, Virani S, Krumholz H, Nasir K
JAMA Cardiol. 2017; 2(12):1369-1374.
PMID: 29049467
PMC: 5814995.
DOI: 10.1001/jamacardio.2017.3655.
Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
Jowett S, Barton P, Roalfe A, Fletcher K, Hobbs F, McManus R
PLoS One. 2017; 12(9):e0182625.
PMID: 28873416
PMC: 5584935.
DOI: 10.1371/journal.pone.0182625.
Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients.
Hallinen T, Soini E, Linna M, Saarni S
Springerplus. 2016; 5(1):1354.
PMID: 27588247
PMC: 4988956.
DOI: 10.1186/s40064-016-3024-5.
Prevalence of Atrial Fibrillation and Relation to Echocardiographic Parameters in a Healthy Asymptomatic Rural Korean Population.
Park H, Park J, Choi S, Kim S, Kim M, Choi B
J Korean Med Sci. 2015; 30(8):1078-84.
PMID: 26240485
PMC: 4520938.
DOI: 10.3346/jkms.2015.30.8.1078.
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
Dorian P, Kongnakorn T, Phatak H, Rublee D, Kuznik A, Lanitis T
Eur Heart J. 2014; 35(28):1897-906.
PMID: 24513791
PMC: 4104492.
DOI: 10.1093/eurheartj/ehu006.
Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions.
Getsios D, Marton J, Revankar N, Ward A, Willke R, Rublee D
Pharmacoeconomics. 2013; 31(9):767-80.
PMID: 23821436
DOI: 10.1007/s40273-013-0070-5.
Excess long-term mortality following non-variceal upper gastrointestinal bleeding: a population-based cohort study.
Crooks C, Card T, West J
PLoS Med. 2013; 10(4):e1001437.
PMID: 23637580
PMC: 3640094.
DOI: 10.1371/journal.pmed.1001437.
Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction.
Ito K, Shrank W, Avorn J, Patrick A, Brennan T, Antman E
Health Serv Res. 2012; 47(6):2097-117.
PMID: 22998129
PMC: 3523366.
DOI: 10.1111/j.1475-6773.2012.01462.x.
Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines.
Sussman J, Vijan S, Choi H, Hayward R
Circ Cardiovasc Qual Outcomes. 2011; 4(3):268-75.
PMID: 21487091
PMC: 4039386.
DOI: 10.1161/CIRCOUTCOMES.110.959239.
Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT).
Lang I, Forman S, Maggioni A, Ruzyllo W, Renkin J, Vozzi C
EuroIntervention. 2010; 5(5):610-8.
PMID: 20142183
PMC: 2893563.
DOI: 10.4244/eijv5i5a98.